Silicon Labs Reports Third Quarter 2026 Results
Quarterly profitability returned, but nine-month operating cash flow fell to $37.198 million from $87.358 million.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Silicon Labs (NASDAQ: SLAB) reported third-quarter revenue of $251 million, with growth across both business segments and a return to GAAP profitability. Revenue rose 22% year over year and 10% sequentially for the quarter ended October 3, 2026. Industrial & Commercial revenue increased 20% to $141 million; Home & Life revenue rose 24% to $110 million. Medical revenue increased 48% sequentially and more than 300% year over year.
GAAP diluted EPS was $0.26, versus a year-earlier loss of $0.30. Non-GAAP diluted EPS reached $1.05, up 228%. GAAP gross margin was 60.8%, and operating income was $7.951 million. Nine-month operating cash flow fell to $37.198 million from $87.358 million, despite a narrower net loss. Silicon Labs suspended forward-looking guidance because of its pending acquisition by Texas Instruments.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointThird-quarter revenue of $251 million rose 22% year over year and 10% sequentially.
- Moderate pointGAAP diluted EPS of $0.26 reversed a year-earlier loss of $0.30.
- Moderate pointNine-month net loss narrowed to $17.638 million from $62.223 million, but remained a loss.
- Minor pointIndustrial & Commercial revenue of $141 million increased 20% year over year.
- Minor pointHome & Life revenue of $110 million increased 24% year over year.
5 minor points
- Minor pointMedical revenue reached a quarterly record, rising 48% sequentially and more than 300% year over year.
- Minor pointGAAP operating income of $7.951 million reversed a year-earlier operating loss of $12.342 million.
- Minor pointNon-GAAP diluted EPS of $1.05 increased 228% year over year.
- Minor pointNine-month revenue of $692.581 million exceeded $576.558 million in the comparable 2025 period.
- Minor pointCash and cash equivalents rose to $423.013 million from $364.222 million at January 3, 2026.
Negative
- Major pointForward-looking guidance suspended because of the pending Texas Instruments acquisition.
- Moderate pointTexas Instruments acquisition remains pending, rather than completed.
- Moderate pointNine-month operating cash flow fell to $37.198 million from $87.358 million a year earlier.
- Minor pointQuarterly GAAP operating expenses rose to $144.627 million from $131.361 million a year earlier.
- Minor pointInventory used $37.828 million of cash over nine months, versus providing $23.316 million a year earlier.
2 minor points
- Minor pointNine-month capital spending increased to $28.472 million from $19.942 million a year earlier.
- Minor pointTotal liabilities increased to $210.772 million from $174.899 million at January 3, 2026.
News Explained
At October 3, 2026, Silicon Labs reported $423,013 thousand in cash and equivalents and $16,828 thousand in short-term investments.
In its third-quarter results, Silicon Labs reports 33,384 thousand common shares issued and outstanding at
At
AI-generated analysis. How Rhea-AI works. Not financial advice.
Wireless IoT leader delivers
"We delivered strong third-quarter results, with revenue up
Third Quarter Financial Highlights
- Revenue was
, up$251 million 22% year-over-year - Industrial & Commercial revenue was
, up$141 million 20% year-over-year - Home & Life revenue was
, up$110 million 24% year-over-year - Bookings imply a healthy demand environment, while distributor inventory declined further to a multi-year low and end customer inventory was near record lows during the quarter
- Medical revenue reached a new quarterly record, increasing
48% sequentially and more than300% year-over-year - GAAP diluted earnings per share was
, compared with a loss of$0.26 in the year-ago quarter$0.30 - Non-GAAP diluted earnings per share was
, up$1.05 228% over the comparable period last year
Results on a GAAP basis:
- GAAP gross margin was
60.8% - GAAP operating expenses were
$145 million - GAAP operating income was
$8 million - GAAP diluted earnings per share was
$0.26
Results on a non-GAAP basis, excluding the impact of stock compensation, amortization of acquired intangible assets, merger-related costs, and certain other items as set forth in the below GAAP to Non-GAAP reconciliation tables were as follows:
- Non-GAAP gross margin was
61.0% - Non-GAAP operating expenses were
$113 million - Non-GAAP operating income was
$40 million - Non-GAAP diluted earnings per share was
$1.05
Due to the announced pending acquisition of Silicon Labs by Texas Instruments, Silicon Labs has suspended providing forward-looking guidance.
About Silicon Labs
Silicon Labs (NASDAQ: SLAB) is the leading innovator in low-power wireless connectivity, building embedded technology that connects devices and improves lives. Merging cutting-edge technology into the world's most highly integrated SoCs, Silicon Labs provides device makers the solutions, support, and ecosystems needed to create advanced edge connectivity applications. Headquartered in
Forward-Looking Statements
This press release contains forward-looking statements regarding Silicon Labs' current expectations, which are based on its current views and assumptions. The words "believe", "estimate", "expect", "intend", "anticipate", "plan", "project", "will", and similar phrases as they relate to Silicon Labs are intended to identify such forward-looking statements, although the absence of such words does not necessarily mean a statement is not forward looking. These forward-looking statements include, but are not necessarily limited to, Silicon Labs' expectations regarding its near- and long-term strength and continued revenue growth and earnings expansion and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations that are expressed or implied herein. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are the following: our ability to complete the merger with Texas Instruments within the time frame expected, or at all, as well as potential disruptions in our business and restrictions on our activities during the pendency of the merger; fluctuating changes in global trade policies, including the imposition of tariffs, duties, trade sanctions, or other barriers to international commerce; the impact of the current global memory chip shortage; the competitive and cyclical nature of the semiconductor industry; the challenging macroeconomic environment, including disruptions in the financial services industry; geographic concentration of manufacturers, assemblers, test service providers and customers in
Note to editors: Silicon Laboratories, Silicon Labs, the "S" symbol, and the Silicon Labs logo are trademarks of Silicon Laboratories Inc. All other product names noted herein may be trademarks of their respective holders.
For more information: Silicon Labs Investor Relations, investor.relations@silabs.com
|
Silicon Laboratories Inc. Condensed Consolidated Statements of Operations (In thousands, except per share data) (Unaudited) |
|||||||
|
|
|
|
|
||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||
|
|
October 3, |
|
October 4, |
|
October 3, |
|
October 4, |
|
Revenues |
$ 250,892 |
|
$ 205,999 |
|
$ 692,581 |
|
$ 576,558 |
|
Cost of revenues |
98,314 |
|
86,980 |
|
272,331 |
|
251,653 |
|
Gross profit |
152,578 |
|
119,019 |
|
420,250 |
|
324,905 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
Research and development |
93,174 |
|
87,685 |
|
276,784 |
|
263,725 |
|
Selling, general and administrative |
51,453 |
|
43,676 |
|
163,263 |
|
128,469 |
|
Operating expenses |
144,627 |
|
131,361 |
|
440,047 |
|
392,194 |
|
Operating income (loss) |
7,951 |
|
(12,342) |
|
(19,797) |
|
(67,289) |
|
Other income (expense): |
|
|
|
|
|
|
|
|
Interest income and other, net |
3,185 |
|
3,046 |
|
9,300 |
|
10,672 |
|
Interest expense |
(226) |
|
(226) |
|
(709) |
|
(761) |
|
Income (loss) before income taxes |
10,910 |
|
(9,522) |
|
(11,206) |
|
(57,378) |
|
Provision for income taxes |
2,059 |
|
414 |
|
6,432 |
|
4,845 |
|
Net income (loss) |
$ 8,851 |
|
$ (9,936) |
|
$ (17,638) |
|
$ (62,223) |
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per share: |
|
|
|
|
|
|
|
|
Basic |
$ 0.27 |
|
$ (0.30) |
|
$ (0.53) |
|
$ (1.91) |
|
Diluted |
$ 0.26 |
|
$ (0.30) |
|
$ (0.53) |
|
$ (1.91) |
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding: |
|
|
|
|
|
|
|
|
Basic |
33,376 |
|
32,835 |
|
33,182 |
|
32,656 |
|
Diluted |
33,752 |
|
32,835 |
|
33,182 |
|
32,656 |
Non-GAAP Financial Measurements
In addition to the GAAP results provided throughout this document, Silicon Labs has provided non-GAAP financial measurements on a basis excluding non-cash and other charges and benefits. Details of these excluded items are presented in the tables below, which reconcile the GAAP results to non-GAAP financial measurements.
The non-GAAP financial measurements do not replace the presentation of Silicon Labs' GAAP financial results. These measurements provide supplemental information to assist management and investors in analyzing Silicon Labs' financial position and results of operations. Silicon Labs has chosen to provide this information to investors to enable them to perform meaningful comparisons of past, present and future operating results and as a means to emphasize the results of core on-going operations.
|
Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except per share data) |
||||||||||||||
|
|
|
|
||||||||||||
|
|
|
Three Months Ended October 3, 2026 |
||||||||||||
|
Non-GAAP Income Statement Items |
|
GAAP Measure |
|
GAAP Percent of Revenue |
|
Stock Compensation Expense |
|
Intangible Amortization |
|
Merger- |
|
Non- Measure |
|
Non-GAAP Percent of Revenue |
|
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
152,578 |
|
60.8 % |
|
$ 459 |
|
$ — |
|
$ — |
|
|
|
61.0 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
93,174 |
|
37.1 % |
|
11,996 |
|
2,295 |
|
3,623 |
|
75,260 |
|
30.0 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative |
|
51,453 |
|
20.5 % |
|
10,594 |
|
— |
|
3,281 |
|
37,578 |
|
15.0 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
144,627 |
|
57.6 % |
|
22,590 |
|
2,295 |
|
6,904 |
|
112,838 |
|
45.0 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
7,951 |
|
3.2 % |
|
23,049 |
|
2,295 |
|
6,904 |
|
40,199 |
|
16.0 % |
|
|
|
Three Months Ended October 3, 2026 |
||||||||||
|
Non-GAAP Earnings Per Share |
|
GAAP Measure |
|
Stock Compensation Expense* |
|
Intangible Asset Amortization* |
|
Merger- |
|
Income Tax Adjustments** |
|
Non- GAAP Measure |
|
Net income (loss) |
|
$ 8,851 |
|
$ 23,049 |
|
$ 2,295 |
|
$ 6,904 |
|
$ (5,710) |
|
$ 35,389 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Diluted shares outstanding |
|
33,752 |
|
|
|
33,752 |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share |
|
$ 0.26 |
|
|
|
|
|
|
|
|
|
$ 1.05 |
|
* Represents pre-tax amounts |
|
** Represents the application of an |
|
Silicon Laboratories Inc. Condensed Consolidated Balance Sheets (In thousands, except per share data) (Unaudited) |
|||
|
|
|
|
|
|
|
October 3, |
|
January 3, |
|
Assets |
|
|
|
|
Current assets: |
|
|
|
|
Cash and cash equivalents |
$ 423,013 |
|
$ 364,222 |
|
Short-term investments |
16,828 |
|
79,400 |
|
Accounts receivable, net |
79,966 |
|
64,513 |
|
Inventories |
133,391 |
|
95,566 |
|
Prepaid expenses and other current assets |
71,421 |
|
70,316 |
|
Total current assets |
724,619 |
|
674,017 |
|
Property and equipment, net |
131,687 |
|
128,643 |
|
Goodwill |
376,389 |
|
376,389 |
|
Other intangible assets, net |
16,246 |
|
23,130 |
|
Other assets, net |
87,213 |
|
67,138 |
|
Total assets |
$ 1,336,154 |
|
$ 1,269,317 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
Current liabilities: |
|
|
|
|
Accounts payable |
$ 68,860 |
|
$ 50,717 |
|
Deferred revenue and returns liability |
9,804 |
|
5,359 |
|
Other current liabilities |
78,841 |
|
87,711 |
|
Total current liabilities |
157,505 |
|
143,787 |
|
Other non-current liabilities |
53,267 |
|
31,112 |
|
Total liabilities |
210,772 |
|
174,899 |
|
Commitments and contingencies |
|
|
|
|
Stockholders' equity: |
|
|
|
|
Preferred stock – |
— |
|
— |
|
Common stock – |
3 |
|
3 |
|
Additional paid-in capital |
206,203 |
|
157,402 |
|
Retained earnings |
919,176 |
|
936,814 |
|
Accumulated other comprehensive income |
— |
|
199 |
|
Total stockholders' equity |
1,125,382 |
|
1,094,418 |
|
Total liabilities and stockholders' equity |
$ 1,336,154 |
|
$ 1,269,317 |
|
Silicon Laboratories Inc. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) |
|||
|
|
|
||
|
|
Nine Months Ended |
||
|
|
October 3, |
|
October 4, |
|
Operating Activities |
|
|
|
|
Net loss |
$ (17,638) |
|
$ (62,223) |
|
Adjustments to reconcile net loss to net cash provided by operating activities: |
|
|
|
|
Depreciation of property and equipment |
18,154 |
|
18,769 |
|
Amortization of other intangible assets |
6,884 |
|
11,074 |
|
Stock-based compensation expense |
69,754 |
|
59,645 |
|
Deferred income taxes |
2,164 |
|
2,026 |
|
Changes in operating assets and liabilities: |
|
|
|
|
Accounts receivable |
(15,453) |
|
(12,829) |
|
Inventories |
(37,828) |
|
23,316 |
|
Prepaid expenses and other assets |
(35,213) |
|
9,080 |
|
Accounts payable |
18,373 |
|
11,141 |
|
Other current liabilities and income taxes |
3,271 |
|
29,901 |
|
Deferred revenue and returns liability |
4,445 |
|
5,374 |
|
Other non-current liabilities |
20,285 |
|
(7,916) |
|
Net cash provided by operating activities |
37,198 |
|
87,358 |
|
|
|
|
|
|
Investing Activities |
|
|
|
|
Purchases of marketable securities |
— |
|
(34,790) |
|
Sales of marketable securities |
— |
|
15,332 |
|
Maturities of marketable securities |
62,309 |
|
22,598 |
|
Purchases of property and equipment |
(28,472) |
|
(19,942) |
|
Proceeds from capital-related government incentives |
8,705 |
|
— |
|
Purchase of other investment |
— |
|
(4,000) |
|
Net cash provided by (used in) investing activities |
42,542 |
|
(20,802) |
|
|
|
|
|
|
Financing Activities |
|
|
|
|
Payment of taxes withheld for vested stock awards |
(28,710) |
|
(14,907) |
|
Proceeds from the issuance of common stock |
7,761 |
|
8,147 |
|
Net cash used in financing activities |
(20,949) |
|
(6,760) |
|
|
|
|
|
|
Increase in cash and cash equivalents |
58,791 |
|
59,796 |
|
Cash and cash equivalents at beginning of period |
364,222 |
|
281,607 |
|
Cash and cash equivalents at end of period |
$ 423,013 |
|
$ 341,403 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/silicon-labs-reports-third-quarter-2026-results-302935539.html
SOURCE Silicon Labs
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Silicon Labs' third-quarter 2026 revenue and earnings?
Silicon Labs reported $251 million in revenue and $0.26 in GAAP diluted EPS for the quarter ended October 3, 2026. Revenue increased 22% year over year, while GAAP diluted EPS improved from a loss of $0.30. Non-GAAP diluted EPS was $1.05, up 228%.
Why did Silicon Labs suspend its financial guidance?
Silicon Labs suspended forward-looking guidance because of its announced pending acquisition by Texas Instruments.
What adjustments explain Silicon Labs' third-quarter 2026 non-GAAP earnings?
Silicon Labs' non-GAAP reconciliation excludes $23.049 million in stock compensation, $2.295 million in intangible asset amortization and $6.904 million in merger-related costs, with a negative $5.710 million income-tax adjustment. These adjustments reconcile GAAP net income of $8.851 million to non-GAAP net income of $35.389 million.
What did Silicon Labs report about customer and distributor inventories in the third quarter of 2026?
Distributor inventory declined further to a multi-year low, while end-customer inventory was near record lows during the quarter. Silicon Labs characterized bookings as indicating a healthy demand environment.